Kailera Therapeutics, Inc.
No annual data found.
Kailera reports Q1 2026 results as clinical-stage biotech, initiates five late-stage obesity trials and reports positive clinical data from partner programs
“Our ribupatide franchise continues to demonstrate category-leading potential among obesity management medications”
| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-20 | 2026-04-22 | RTW INVESTMENTS, LP | 10% Owner | Purchase | 500.0K | $16.00 | $8.00M | 10.78M | View | |
| 2026-04-20 | 2026-04-20 | BAIN CAPITAL INVESTORS LLC | 10% Owner | Purchase | 8.40M | $16.00 | $134.38M | 26.26M | View | |
| 2026-04-20 | 2026-04-20 | Koppel Adam | Director | Purchase | 1.56M | $16.00 | $25.00M | 22.58M | View |
Informational purposes only, not investment advice.